Pilocarpine Hydrochloride

Mechanism

Pharmacological Class and Group

Direct acting parasympathomimetic agent. Non-selective muscarinic cholinergic agonist.

Mechanism of Action

Pilocarpine stimulates the exocrine glands innervated by the parasympathetic nervous system through specific muscarinic receptors:

Salivary Secretion Stimulation Mechanism

1. Binding to Muscarinic M3 Receptors: It selectively binds to the M3 type acetylcholine receptors present in the basolateral membranes of the acinar cells of the major salivary glands (parotid, submandibular and sublingual) and minor salivary glands of the oral cavity.

2. Activation of Protein Gq and Increase in Cytoplasmic Calcium: Stimulation of M3 activates the protein Gq/phospholipase C cascade, which increases cellular levels of inositol triphosphate (IP3) and releases calcium stored in the endoplasmic reticulum of acinar cells.

3. Opening of Chlorine Channels and Water Flow: The increase in intracellular calcium opens the apical chlorine channels. Chlorine actively moves to the lumen of the glandular acinus, passively dragging sodium cations and free water through cellular tight junctions and aquaporins:

Stimulation of M₃ Receptors ↑ Intracellular calcium ↑ Flow of fluid saliva of serous origin

This increase in fluid salivary secretion relieves the symptoms of deep dry mouth (xerostomia), improving swallowing, phonation and reducing the risk of local opportunistic infections (ascending parotitis, oral candidiasis).

Pharmacokinetics

High Resolution Pharmacokinetics

• Absorption and Bioavailability: Rapid absorption in the gastrointestinal tract. The peak of maximum plasma concentration (C_max) is reached between 1 and 1.25 hours after taking on an empty stomach. Consumption of foods rich in fat delays and reduces the rate of plasma absorption of the drug.
• Distribution: Wide distribution in exocrine tissues. Low binding to circulating plasma proteins.
• Metabolism: Mainly demethylation and local hydrolysis to inactive metabolites such as pilocarpic acid, independent of hepatic cytochrome CYP450.
• Excretion: Most renal excretion as polar inactive metabolites.
• Half-life (t_1/2): Short, approximately 0.76 to 1.35 hours, which requires the administration of repeated doses (3 to 4 times a day) to maintain the secretory stimulus.

Indicators and dose

Clinical Indications and Off-Label Uses

• Xerostomia Secondary to Head and Neck Radiotherapy: Relief of persistent oral dryness in cancer patients who preserve functional parenchyma in the salivary glands.
• Primary or Secondary Sjögren's Syndrome: Systemic treatment of dry eyes (keratoconjunctivitis sicca) and severe oral dryness in combination with immunomodulators.
• Refractory salivary dysfunction induced by psychotropic drugs (off-label): Mitigation of deep dryness secondary to treatment with tricyclic antidepressants, antipsychotics or lithium.

Dosage and Clinical Adjustment

Xerostomia due to Radiotherapy:

• Initial Dose: 5 mg orally three times a day (total daily dose of 15 mg).
• Titration: If there is no improvement after 4 weeks of use and it is adequately tolerated, it can be gradually increased to a maximum dose of 10 mg orally three times a day (daily dose of 30 mg).

Sjögren's syndrome:

• 5 mg orally four times a day (with breakfast, lunch, dinner and before bedtime).

Adjustment in Renal or Liver Failure:

• In patients with Moderate to Severe Liver Failure (Child-Pugh B or C), the half-life is lengthened. It should be started with a reduced dose of 2.5 mg to 5 mg once or twice a day, titrated according to clinical response and closely monitoring cholinergic ADRs.

Security

Absolute and Relative Contraindications

Absolute Contraindications

• Known hypersensitivity to pilocarpine or other direct cholinergic agonists.
• Active bronchial asthma or severe uncontrolled COPD: The systemic muscarinic stimulus induces bronconstriction and increased viscosity of bronchial secretions, precipitating acute respiratory failure.
• Untreated narrow-angle glaucoma or acute iritis.

Relative Contraindications

• Decompensated congestive heart failure or underlying sinus bradycardia (may be worsened by vagotonic stimulation).
• Severe gastroesophageal reflux disease or active peptic ulcer (increases gastric acidity and digestive spasm).
• Active cholelithiasis or urolithiasis (the stimulation of biliary and ureteral contraction can trigger severe colic).

Adverse Effects (ADR) and Specific Toxicity

• Very common (>10%): Massive diaphoresis (dose-dependent profuse sweating; occurs in up to 30% of patients due to direct stimulation of the sweat glands, being the most common limiting side effect).
• Common (1%-10%): Supraorbital headache, transient watery rhinitis, increased lacrimation, hot flashes (facial flushing), dysuria, frequency (urinary urgency due to contraction of the bladder detrusor muscle), nausea, colic diarrhea.
• Rare (<0.1%): Marked sinus bradycardia, transient atrioventricular blocks, severe airway bronchospasm, blurred vision due to spasm of the accommodative ciliary muscle.

Clinical Alert: Management of Pilocarpine Diaphoresis

Profuse diaphoresis induced by pilocarpine is usually dose-dependent. If the patient experiences episodes of uncomfortable sweating and mild dehydration, it is recommended to reduce the dose by 50% (e.g., to 2.5 mg three times a day) and begin a very slow gradual escalation over a period of 4 to 6 weeks, always administering the drug together with plenty of free water to compensate for water losses.

Drug Interactions of Clinical Relevance

• Anticholinergics with systemic action (Atropine, Scopolamine, Ipratropium, Biperiden): Direct pharmacodynamic antagonistic interaction. They completely annul the cholinergic effect of pilocarpine, worsening xerostomia.
• Beta Adrenergic Blockers (Metoprolol, Propranolol): Negative pharmacodynamic synergism on cardiac conduction, severely increasing the risk of profound bradycardia, syncope of vasovagal origin or conduction arrhythmias.

Safety in Pregnancy and Breastfeeding

• Pregnancy: Contraindicated. Experimental studies in animal models show direct fetal embryotoxicity and increased abortion rate. There are no controlled studies in human pregnant women.
• Breastfeeding: Not recommended. It is unknown whether pilocarpine is excreted in breast milk; The cardiovascular or respiratory safety of the infant cannot be guaranteed.